



US007375193B2

(12) **United States Patent**
Baca et al.

(10) **Patent No.:** **US 7,375,193 B2**
(45) **Date of Patent:** **May 20, 2008**

(54) **ANTI-VEGF ANTIBODIES**
(75) Inventors: **Manuel Baca**, Black Rock (AU);
James A. Wells, Burlingame, CA (US);
Leonard G. Presta, San Francisco, CA
(US); **Henry B. Lowman**, El Granada,
CA (US); **Yvonne Man-Yee Chen**, San
Mateo, CA (US)

WO WO 92/18619 10/1992
WO WO 92/22653 12/1992
WO WO 94/04679 3/1994
WO WO 94/10202 5/1994
WO 96/30046 10/1996
WO WO 98/45331 10/1998
WO WO 98/45332 10/1998

(73) Assignee: **Genentech, Inc.**, South San Francisco,
CA (US)

OTHER PUBLICATIONS

(*) Notice: Subject to any disclaimer, the term of this
patent is extended or adjusted under 35
U.S.C. 154(b) by 0 days.

Adamis et al., "Inhibition of Vascular Endothelial Growth Factor
Prevents Retinal Ischemia-Associated Iris Neovascularization in a
Nonhuman Primate" *Arch. Ophthalmology* 114(1) :66-71 (1996).
Aiello et al., "Vascular endothelial growth factor in ocular fluid of
patients with diabetic retinopathy and other retinal disorders" *New
England J. of Medicine* 331(22) :1480-1487 (1994).

(21) Appl. No.: **11/537,015**

Alberts et al., "Molecular Biology of the Cell", 3rd edition, Garland
Publishing pp. 1154 (1994).

(22) Filed: **Sep. 29, 2006**

Allen et al., "Specificity of the T cell Receptor: Two Different
Determinates are Generated by the Same Peptide and the IAK
Molecule" *J. Immunol.* 135(1) :368-373 (Jul. 1985).

(65) **Prior Publication Data**

US 2007/0248610 A1 Oct. 25, 2007

Amit et al., "Three-Dimensional Structure of an Antigen-Antibody
Complex at 2.8 Å Resolution" *Science* 233:747-753 (Aug. 1986).

Related U.S. Application Data

Baca et al., "Antibody Humanization Using Monovalent Phage
Display" *Journal of Biological Chemistry* 272(16) :10678-10684
(1997).

(60) Continuation of application No. 10/974,591, filed on
Oct. 26, 2004, now Pat. No. 7,297,334, which is a
continuation of application No. 09/723,752, filed on
Nov. 27, 2000, now Pat. No. 7,060,269, which is a
division of application No. 08/908,469, filed on Aug.
6, 1997, now Pat. No. 6,884,879.

Bass et al., "Hormone Phage: An Enrichment Method for Variant
Proteins with Altered Binding Properties" *Proteins: Structure,
Function, and Genetics* 8(4) :309-314 (1990).

(60) Provisional application No. 60/126,446, filed on Apr.
7, 1997.

Bendig, M. M., "Humanization of Rodent Monoclonal Antibodies"
Methods: A Companion to Methods in Enzymology 8:83-93 (1994).

(51) **Int. Cl.**
C07K 16/00 (2006.01)

Berkman et al., "Expression of the vascular permeability factor/
vascular endothelial growth factor gene in central nervous system
neoplasms" *J. Clin. Invest.* 91(1) :153-159 (1993).

(52) **U.S. Cl.** **530/387.1; 530/387.3;**
530/388.85; 424/130.1; 435/320.1; 536/23.53

Borgstrom et al., "Complete inhibition of angiogenesis and growth
of microtumors by anti-vascular endothelial growth factor neutral-
izing antibody: novel concepts of angiostatic therapy from intravitral
videomicroscopy" *Cancer Research* 56(17) :4032-4039 (Sep. 1,
1996).

(58) **Field of Classification Search** **530/387.1,**
530/387.3, 388.85; 424/130.1; 435/320.1;
536/23.53

Brown et al., "Expression of vascular permeability factor (vascular
endothelial growth factor) and its receptors in adenocarcinomas of
the gastrointestinal tract" *Cancer Research* 53(19) :4727-4735
(1993).

See application file for complete search history.

Brown et al., "Expression of vascular permeability factor (vascular
endothelial growth factor) and its receptors in breast cancer" *Human
Pathology* 26(1) :86-91 (1995).

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,816,567 A 3/1989 Cabilly et al.
5,530,101 A 6/1996 Queen et al.
5,580,723 A 12/1996 Wells et al.
6,037,454 A 3/2000 Jardieu et al.
6,054,297 A 4/2000 Carter et al.
6,884,879 B1 4/2005 Baca et al.
7,060,269 B1 6/2006 Baca et al.
7,169,901 B2* 1/2007 Baca et al. 530/387.1
2002/0032315 A1 3/2002 Baca et al.

Carter et al., "Humanization of an Anti-p185^{HER2} Antibody for
Human Cancer Therapy" *Proc. Natl. Acad. Sci. USA* 89(10) :4285-
4289 (May 1992).

(Continued)

Primary Examiner—David J. Blanchard
Assistant Examiner—Parithosh K. Tungaturthi

FOREIGN PATENT DOCUMENTS

EP 0239400 9/1987
EP 0451216 1/1996
EP 451216 B1 1/1996
EP 1 325 932 B1 4/2005
GB 2188638 10/1987
GB 2268744 12/1994
WO 91/0996 1/1991
WO WO 91/09967 7/1991

(57) **ABSTRACT**

Humanized and variant anti-VEGF antibodies and various
uses therefor are disclosed. The anti-VEGF antibodies have
strong binding affinities for VEGF; inhibit VEGF-induced
proliferation of endothelial cells in vitro; and inhibit tumor
growth in vivo.

22 Claims, 16 Drawing Sheets

OTHER PUBLICATIONS

- Chang et al., "High-Level Secretion of Human Growth Hormone by *Escherichia coli*" *Gene* 55:189-196 (1987).
- Chen et al., "Selection and Analysis of an Optimized Anti-VEGF Antibody: Crystal Structure of an Affinity-matured Fab in Complex with Antigen" *Journal of Molecular Biology* 293(4) :865-881 (1999).
- Chisholm, "High Efficiency Gene Transfer into Mammalian Cells" *DNA Cloning 4. Mammalian Systems* pp. 1-41 (1995).
- Chothia et al., "Domain Association in Immunoglobulin Molecules. The Packing of Variable Domains" *Journal of Molecular Biology* 186(3) :651-663 (Dec. 5, 1985).
- Clackson et al., "Making Antibody Fragments Using Phage Display Libraries" *Nature* 352(15) :624-628 (Aug. 1991).
- Clapp et al., "The 16-kilodalton N-terminal fragment of human prolactin is a potent inhibitor of angiogenesis" *Endocrinology* 133(3) :1292-1299 (1993).
- Coleman, P.M., "Effects of amino acid sequence changes on antibody-antigen interactions" *Research in Immunology* 145:33-36 (1994).
- Colman P.M., "Effects of amino acid sequence changes on antibody-antigen interactions" *Research in Immunology* 145:33-36 (1994).
- Cunningham et al., "Production of an Atrial Natriuretic Peptide Variant that is Specific for Type A Receptor" *EMBO Journal* 13(11) : 2508-2515 (1994).
- De Vries et al., "The fms-like tyrosine kinase, a receptor for vascular endothelial growth factor" *Science* 255:989-991 (1992).
- Dvorak et al., "Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis" *American Journal of Pathology* 146(5) :1029-1039 (1995).
- Eaton et al., "Construction and characterization of an active factor VIII variant lacking the central one-third of the molecule" *Biochemistry* 25:8343-8347 (1986).
- Eigenbrot et al., "X-Ray Structures of Fragments From Binding and Nonbinding Versions of a Humanized Anti-CD18 Antibody: Structural Indications of the Key Role of V_H Residues 59 to 65" *Proteins: Structure, Function, and Genetics* 18:49-62 (1994).
- Eigenbrot et al., "X-Ray Structures of the Antigen-Binding Domains From Three Variants of Humanized Anti-p185^{HER2} Antibody 4D5 and Comparison With Molecular Modeling" *J. Mol. Biol.* 229:969-995 (1993).
- Ferrara and Davis-Smyth, "The Biology of Vascular Endothelial Growth Factor" *Endocrine Reviews* 18(1) :4-25 (1997).
- Folkman and Shing, "Angiogenesis" *Journal of Biological Chemistry* 267:10931-10934 (1992).
- Foote et al., "Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops" *J. Mol. Biol.* 224:487-499 (1992).
- Garner, A., "Vascular Diseases" *Pathobiology of Ocular Disease. A Dynamic Approach*, Garner, A., Klintworth GK Eds., 2nd edition, NY:Marcel Dekker pp. 1625-1710 (1994).
- Garrard et al., "Assembly and Enrichment in a Monovalent Phage Display System" *Biotechnology* 9:1373-1377 (1997).
- Garrard et al., "Fab assembly and enrichment in a monovalent phage display system" *Bio/technology* 9:1373-1377 (1991).
- Good et al., "A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin" *Proc. Natl. Acad. Sci. USA* 87(17) :6624-6628 (1990).
- Gorman et al., "Transient Production of Proteins Using an Adenovirus Transformed Cell Line" *DNA Prot. Eng. Tech.* 2(1) : 3-10 (1990).
- Graham et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5" *J. Gen. Virol.* 36:59-72 (1977).
- Hawkins et al., "Selection of Phage Antibodies by Binding Affinity Mimicking Affinity Maturation" *J. Mol. Biol.* 226:889-896 (1992).
- Horak et al., "Angiogenesis, assessed by platelet/endothelial cell Ibragimova and Wade, "Stability of the β -sheet of the WW Domain: A Molecular Dynamics Simulation Study" *Biophysical Journal* 77:2191-2198 (Oct. 1999).
- Kabat et al. *Sequences of Proteins of Immunological Interest*, U.S. Dept. of Health and Human Services, NIH, 5th edition vol. 1:103-108, 324-331 (1991).
- Karlsson et al., "Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system" *J. Immun. Methods* 145:229-240 (1991).
- Karlsson et al., "Kinetic and Concentration Analysis Using BIA Technology" *Methods: A Comparison to Methods in Enzymology* 6:99-110 (1994).
- Kettleborough et al., "Humanization of a Mouse Monoclonal Antibody by CDR-grafting: the Importance of Framework Residues on Loop Conformation" *Protein Engineering* 4(7) :773-783 (1991).
- Kim et al., "Inhibition of Vascular Endothelial Growth Factor-Induced Angiogenesis Suppresses Tumour Growth in vivo" *Nature* 362:841-844 (Apr. 29, 1993).
- Kim et al., "The Vascular Endothelial Growth Factor Proteins: Identification of Biologically Relevant Regions by Neutralizing Monoclonal Antibodies" *Growth Factors* 7(1) :53-64 (1992).
- Klagsbrun and D'Amore, "Regulators of angiogenesis" *Ann. Rev. Physiol.* 53:217-239 (1991).
- Kunkel et al., "Efficient site-directed mutagenesis using uracil-containing DNA" *Methods in Enzymology* 204:125-139 (1991).
- Kunkel, T., "Rapid and Efficient Site-Specific Mutagenesis Without Phenotypic Selection" *Proc. Natl. Acad. Sci.* 82(2) :488-492 (Jan. 1985).
- Leung et al., "Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen" *Science* 246(4935) :1306-1309 (Dec. 8, 1989).
- Lopez et al., "Transdifferentiated retinal pigment epithelial cells are immunoreactive for vascular endothelial growth factor in surgically excised age-related macular degeneration-related choroidal neovascular membranes" *Invest. Ophthalmol. Vis. Sci.* 37(5) :855-868 (1996).
- Lowman et al., "Selecting High-Affinity Binding Proteins by Monovalent Phage Display" *Biochemistry* 30(45) :10832-10838 (1991).
- Lucas, et al., "High-Level Production of Recombinant Proteins in CHO Cells Using a Dicitronic DHFR Intron Expression Vector" *Nucleic Acids Research* 24(9) :1774-1779 (1996).
- Macchiarini et al., "Relation of neovascularisation to metastasis of non-small-cell lung cancer" *Lancet* 340(8812) :145-146 (1992).
- Mattern et al., "Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma" *Brit. J. Cancer* 73(7) :931-934 (1996).
- Melnyk et al., "Vascular endothelial growth factor promotes tumor dissemination by a mechanism distinct from its effect on primary tumor growth" *Cancer Research* 56(4) :921-924 (Feb. 15, 1996).
- Novotny et al., "Structural invariants of antigen binding: comparison of immunoglobulin V_L-V_H and V_L-V_L domain dimers" *Proc. Natl. Acad. Sci. USA* 82(14) :4592-4596 (Jul. 1985).
- O'Reilly et al., "Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma" *Cell* 79(2) :315-328 (1994).
- O'Reilly et al., "Endostatin: an endogenous inhibitor of angiogenesis and tumor growth" *Cell* 88(2) :277-285 (1997).
- Padlan, E., "A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties" *Molecular Immunology* 28(4/4) :489-498 (1991).
- Panka et al., "Variable region framework differences result in decreased or increased affinity of variant anti-digoxin antibodies" *Proc. Natl. Acad. Sci. USA* 85:3080-3084 (May 1988).
- Park et al., "Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR" *Journal of Biological Chemistry* 269(41) :25646-25654 (1994).

- Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" *Cancer Research* 57(20) :4593-4599 (Oct. 15, 1997).
- Presta et al., "Humanization of an Antibody Directed Against IgE" *J. Immunol.* 151(5) :2623-2632 (Sep. 1, 1993).
- Queen et al., "A humanized antibody that binds to the interleukin 2 receptor" *Proc. Natl. Acad. Sci. USA* 86(24) :10029-10033 (Dec. 1989).
- Roguska et al., "Humanization of murine monoclonal antibodies through variable domain resurfacing" *Proc. Natl. Acad. Sci. USA* 91:969-973 (Feb. 1994).
- Rosok et al., "A Combinatorial Library Strategy for the Rapid Humanization of Anticarcinoma BR96 Fab" *Journal of Biological Chemistry* 271(37) :22611-22618 (Sep. 13, 1996).
- Rudikoff et al., "Single amino acid substitution altering antigen-binding specificity" *Proc. Natl. Acad. Sci. USA* 79:1979-1983 (1982).
- Sanger et al., "DNA Sequencing with Chain-terminating Inhibitors" *Proc. Natl. Acad. Sci. USA* 74(12) :5463-5467 (Dec. 1977).
- Shalaby et al., "Development of Humanized Bispecific Antibodies Reactive with Cytotoxic Lymphocytes and Tumor Cells Overexpressing the HER2 Protooncogene" *Journal of Experimental Medicine* 175:217-225 (Jan. 1, 1992).
- Studnicka et al., "Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues" *Protein Eng.* 7(6) :805-814 (1994).
- Tempest et al., "Reshaping a Human Monoclonal Antibody to Inhibit Respiratory Syncytial Virus Infection In Vivo" *Bio/Technology* 9:266-271 (Mar. 1991).
- Vieira et al., "Production of Single-stranded Plasmid DNA" *Methods in Enzymology* 153:3-11 (1987).
- Warren et al., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis" *J. Clin. Invest.* 95(4) :1789-1797 (Apr. 1995).
- Weidner et al., "Tumor angiogenesis and metastasis—correlation in invasive breast carcinoma" *New England J. of Medicine* 324(1) :1-8 (1991).
- Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" *J. of Immunology* 157:4986-4995 (1996).
- Winter et al., "Making antibodies by phage display technology" *Annual Review of Immunology* 12:433-455 (1994).
- Yang et al., "CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range" *Journal of Molecular Biology* 254(3) :392-403 (Dec. 1, 1995).
- Yelton et al., "Affinity Maturation of the BR96 Anti-Carcinoma Antibody by Codon-Based Mutagenesis" *The Journal of Immunology* 155:1994-2004 (1995).

* cited by examiner

```

1          10          20          30          40
A4.6.1  EIQLVQSGPELKQPGETVRISCASGYTFTNYGMNWVKQA
      * * * * * * * * * *
F(ab)-12 EVQLVESGGGLVQPGGSLRLSCAASGYTFTNYGMNWVRQA
      * * * * *
humIII  EVQLVESGGGLVQPGGSLRLSCAASGFTTSSYAMSWVRQA

          50 a          60          70          80
A4.6.1  PGKGLKWMGWINTYTGEPTYAADFKRRFTFSLETSASTAYL
      * * * * * * * *
F(ab)-12 PGKGLEWVGWINTYTGEPTYAADFKRRFTFSLDTSKSTAYL
      * * * * * * * *
humIII  PGKGLEWVSVISGDDGSTYADSVKGRFTISRDNSKNTLYL

          abc          90          110
A4.6.1  QISNLKNDTATYFCAKYPHYYGSSHWYFDVWGAGTTVTVSS (SEQ.ID NO:9)
      * * * * * * * *
F(ab)-12 QMNSLRAEDTAVYYCAKYPHYYGSSHWYFDVWGQGTLVTVSS (SEQ.ID NO:7)
      * * * * *
humIII  QMNSLRAEDTAVYYCARG-----FDYWGQGTLVTVSS (SEQ.ID NO:11)

```

FIG. 1A

```

1          10          20          30          40
A4.6.1  DIQMTQTTSSLSASLGDRVIISCSASQDISNYLNWYQQKP
      * * * * *
F(ab)-12 DIQMTQSPSSLSASVGDRVTITCSASQDISNYLNWYQQKP
      * * * * *
humKI  DIQMTQSPSSLSASVGDRVTITCRASQDISNYLAWYQQKP

          50          60          70          80
A4.6.1  DGTVKVLIYFTSSLHSGVPSRFSGSGSGTDYSLTISNLEP
      * * * * * * * *
F(ab)-12 GKAPKVLIYFTSSLHSGVPSRFSGSGSGTDFTLTISLQF
      * * * * *
humKI  GKAPKLLIYAASSLESGVPSRFSGSGSGTDFTLTISLQF

          90          100
A4.6.1  EDIATYYCQOYSTVPWTFGGGKLEIKR (SEQ.ID NO:10)
      * * * * *
F(ab)-12 EDFATYYCQOYSTVPWTFGGGKVEIKR (SEQ.ID NO:8)
      * * * * *
humKI  EDFATYYCQOYNSLPWTFGGGKVEIKR (SEQ.ID NO:12)

```

FIG. 1B




FIG. 2

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.